Renal failure, homocysteine and the pharmacology of vitamin B12

Metabolism: Clinical and Experimental

Volumn 51, Issue 4, 2002, Pages 399-402

  Hoffer, L John ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CORONARY RISK; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; GENETIC DISORDER; HEMODIALYSIS; HIGH RISK POPULATION; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTENOSIS; RISK ASSESSMENT; THROMBOGENESIS; TREATMENT PLANNING; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION; BLOOD; CHRONIC KIDNEY FAILURE; METABOLISM;

HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; VITAMIN B 12;

EID: 0036549195     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.32517     Document Type: Editorial

References (55)

1. Homocysteine and its disulfide derivatives: A suggested consensus terminology
2. Homocysteine and vascular disease
3. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
4. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease
5. Total homocysteine and cardiovascular disease
6. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
7. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L
8. Hyperhomocysteinemia: A risk factor for central retinal vein occlusion
9. Primary prevention of ischemic stroke - A statement for healthcare professionals from the Stroke Council of the American Heart Association
10. Disorders of transsulfuration
11. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism
12. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats
13. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia
14. Homocysteine and atherothrombosis
15. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association
16. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia
17. Effects of homocysteine on endothelial nitric oxide production
18. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine
19. Homocysteine impairs the nitric oxide synthase pathway
20. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels
21. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
22. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
23. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
24. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
25. Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide
26. Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis
27. Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism
28. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
29. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease
30. Treatment with different doses of folic acid in haemodialysis patients: Effects on folate distribution and aminothiol concentrations
31. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
32. Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins
33. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients
34. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients
35. 12 and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia
36. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients
37. Homocysteinemia and vascular disease in end-stage renal disease
38. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
39. Hyperhomocysteinemia in chronic renal disease
40. A tale of two homocysteines - And two hemodialysis units
41. 12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease
42. 12 reduces hyperhomocysteinemia in end-stage renal disease
43. 12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid
44. Treatment of hyperhomocysteinemia in end-stage renal disease
45. 12
46. 12 deficiency
47. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease
48. The kidney and homocysteine metabolism
49. Homocysteine metabolism in renal failure
50. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria
51. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations
52. Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin
53. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
54. Renoprotection: One or many therapies?